Lymphoma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

770 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lymphoma
NCT01744223: Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Active, not recruiting
1/2
36
US
BPX-501 dose 1, rivogenlecleucel, Rimiducid, AP1903, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
10/19
10/32
2019-003317-33: A study to assess the safety and tolerability of multiple doses of CyPep-1 in subjects with advanced cancer.

Not yet recruiting
1/2
84
Europe
CyPep-1, Pembrolizumab, MK-3475, Solution for injection, Solution for infusion, Keytruda
Cytovation ASA, Cytovation AS, Cytovation ASA, Cytovation AS
Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumors or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 that meet one of the following criteria:a. Relapsed following or progressed through standard therapyb. Have a disease for which no standard effective therapy exists., Subjects diagnosed with an advanced or metastatic solid tumor. Currently, there is no standard therapy available to treat this tumor., Diseases [C] - Cancer [C04]
 
 
2019-000111-84: A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin Lymphoma Studio di acalabrutinib da solo o in associazione con Rituximab e Lenalidomidein soggetti con linfoma non Hodgkin a cellule B

Not yet recruiting
1/2
120
Europe
Acalabrutinib, Rituximab, Revlimid®, Revlimid, [ACP-196], [Rituximab], [Revlimid®], [Revlimid], Capsule, hard, Concentrate for solution for infusion, MabThera, Revlimid®
ACERTA PHARMA BV, Acerta Pharma BV
B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, Diseases [C] - Cancer [C04]
 
 
2019-001263-70: Immunotherapy with differentiated T lymphocytes genetically modified in patients with classic Hodgkin's lymphoma and non-Hodgkin's lymphoma T with CD30 expression Inmunoterapia con linfocitos T diferenciados modificados genéticamente en pacientes con linfoma de Hodgkin clásico y linfoma no-hodgkin T con expresión CD30

Not yet recruiting
1/2
30
Europe
Linfocitos HSP-CAR30, Infusion
Institut de Recerca H. de la Santa Creu i Sant Pau, Institut de Recerca H. de la Santa Creu i Sant Pau
Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression Linfoma de Hodgkin clásico y linfoma T con expresión CD30, Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression Linfoma de Hodgkin clásico y linfoma T con expresión CD30, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02227199: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis
University of Washington, National Cancer Institute (NCI), Seagen Inc.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/20
09/25
C25004, NCT02979522 / 2015-004112-38: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting
1/2
59
Europe, Japan, US, RoW
Brentuximab vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine
Takeda
Hodgkin Disease
05/20
09/29
NCT02065869 / 2014-000584-41: Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Checkmark Topline data from BP-004 trial
Jul 2019 - Jul 2019: Topline data from BP-004 trial
Checkmark From BP-004 trial in children with malignant or non-malignant disorders [screenshot]
Dec 2018 - Dec 2018: From BP-004 trial in children with malignant or non-malignant disorders [screenshot]
Checkmark From trials in children with malignant or non-malignant disorders who develop GVHD at ASH 2018 [screenshot]
More
Terminated
1/2
187
Europe
BPX-501 T cells, Rivogenlecleucel, Rimiducid, AP1903
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome, Primary Immunodeficiency, Anemia, Aplastic, Osteopetrosis, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell
06/20
09/21
NCT02328014: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Hourglass Jan 2020 - Dec 2020 : In B-cell malignancies
Active, not recruiting
1/2
40
US
Acalabrutinib, ACP-196, ACP-319
Acerta Pharma BV, AstraZeneca
Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
06/20
04/26
2016-002423-29: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Nivolumab in Select Advanced Cancers

Not yet recruiting
1/2
291
Europe
Epacadostat, Nivolumab, INCB024360, BMS-936558, Tablet, Solution for infusion, Opdivo
incyte Corporation, Incyte Corporation
Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and neck, ovarian cancer, recurrent B cell NHL (including DLBCL) or HL, or glioblastoma., Selected advanced cancers including lung , melanoma, colon or rectum cancer, head and neck , ovarian , B cell non-Hodgkin's lymphoma or Hodgkin's lymphoma, or glioblastoma, Diseases [C] - Cancer [C04]
 
 
NCT03733249 / 2016-003226-16: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Terminated
1/2
187
Europe
Rimiducid, AP1903, rivogenlecleucel, BPX-501
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immunodeficiency, Anemia, Aplastic, Hemoglobinopathies, Cytopenia, Fanconi Anemia, Diamond Blackfan Anemia, Thalassemia, Anemia, Sickle Cell
06/20
04/23
KEYNOTE145, NCT02362035: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Checkmark Data from KEYNOTE145 trial in hematological malignancies
Jan 2023 - Jan 2023: Data from KEYNOTE145 trial in hematological malignancies
Active, not recruiting
1/2
161
US
Acalabrutinib, ACP-196, Pembrolizumab, KEYTRUDA
Acerta Pharma BV, Merck Sharp & Dohme LLC
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
07/20
04/26
2020-002090-10: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human Study of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2, as a Single Agent and with Pembrolizumab in Treatment of Advanced Malignancies

Not yet recruiting
1/2
236
Europe
BI-1808, BI-1808, Concentrate for solution for infusion, KEYTRUDA®
BioInvent International AB, BioInvent International AB
Phase 1, Parts A and Part B of the trial will recruit subjects with all types of malignancies whose tumors have progressed after standard anticancer treatment.Phase 2a, Parts A and Part B of the trial will recruit patients with NSCLC, OC, and CTCL (specifically MF or SS)., Advanced solid tumors, Diseases [C] - Cancer [C04]
 
 
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
CheckMate 039, NCT01592370 / 2018-001030-17: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Checkmark AACR 2016 - relapsed or refractory lymphoid malignancies
Mar 2016 - Mar 2016: AACR 2016 - relapsed or refractory lymphoid malignancies
Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Checkmark ICML 2015
More
Active, not recruiting
1/2
316
Europe, US
Nivolumab, BMS-936558, Opdivo, Ipilimumab, Yervoy, BMS-734016, MDX010, Lirilumab, BMS-986015, Daratumumab, Darzalex, Pomalidomide, Pomalyst, Dexamethasone, Intensol
Bristol-Myers Squibb, Janssen, LP
Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
09/20
12/23
NCT02481310: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
1/2
38
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ixazomib Citrate, MLN-9708, MLN9708, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar BI 695500, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, RTXM83, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, HYDROCORTISONE, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Northwestern University, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
09/20
07/24
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03870945: Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Active, not recruiting
1/2
12
Europe
MB-CART2019.1 Dose level 1, CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells, MB-CART2019.1 Dose level 2
Miltenyi Biomedicine GmbH, ICON plc
B-cell Non Hodgkin Lymphoma
12/20
12/25
2020-003452-32: CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL CD19-CAR_Lenti in pazienti pediatrici affetti da B-ALL recidivata/refrattaria o con Linfoma a Grandi Cellule B (DLCBL) o Linfoma Primitivo del Mediastino a Cellule B (PML)

Not yet recruiting
1/2
32
Europe
Ciclofosfamide monoidrata, CD19-CAR_Lenti, Fludarabina Fosfato, [N.A.], Powder and solvent for solution for infusion, Solution for infusion
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, Miltenyi Biotec GmbH, FONTE DI COPERTURA DEI COSTI codice: 201987_TRIAL_LOCAT (Prof. Franco Locatelli)
relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma B-ALL recidivata/refrattaria o con Linfoma a Grandi Cellule B (DLCBL) o Linfoma Primitivo del Mediastino a Cellule B (PML), Hematological disorders Patologie neoplastiche ematologiche, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03994913: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Completed
1/2
20
RoW
CAR-CD19 T Cells
CARsgen Therapeutics Co., Ltd., First Affiliated Hospital of Zhejiang University, RenJi Hospital
Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma
01/21
05/21
NCT03547700: Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Active, not recruiting
1/2
11
US
Romidepsin, Istodax, Ixazomib, Ninlaro
Ryan Wilcox, University of Michigan Rogel Cancer Center, Takeda
Lymphoma, T-Cell, Peripheral
03/21
07/21
NCT04509466: Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Terminated
1/2
41
RoW
Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 1, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients), Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Extranodal NK/T-cell Lymphoma, Nasal Type
01/22
01/22
NCT03301168: Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Checkmark From trials in children with malignant or non-malignant disorders who develop GVHD at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From trials in children with malignant or non-malignant disorders who develop GVHD at ASH 2018 [screenshot]
Active, not recruiting
1/2
120
US
BPX-501 T cells, rivogenlecleucel, Rimiducid, AP1903
Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic
05/21
05/34
NCT03265106: A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Active, not recruiting
1/2
20
RoW
BinD19
Shenzhen BinDeBio Ltd., Children's Hospital of Fudan University
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood
05/21
12/21
NCT03156101: A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Active, not recruiting
1/2
24
RoW
BinD19
Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University
Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed／Refractory B-cell Lymphoma
05/21
12/21
2020-003947-27: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Solid Tumors or Hematologic Malignancies

Not yet recruiting
1/2
132
Europe
TAK-981, TAK-981, Solution for infusion
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc. (TDC Americas)
Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies, Solid Tumors or Hematologic Malignancies, Diseases [C] - Cancer [C04]
 
 
ACE-CL-001, NCT02029443 / 2014-000440-15: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Checkmark Presentation of data from Phase 1/2 trial in 1L CLL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from Phase 1/2 trial in 1L CLL at ASH 2022
Checkmark Data from ACE-CL-001 trial for treatment-naive CLL at EHA 2020
Jun 2020 - Jun 2020: Data from ACE-CL-001 trial for treatment-naive CLL at EHA 2020
Checkmark Data from CL-001 trial for treatment-naive CLL at ASCO 2020
More
Active, not recruiting
1/2
306
Europe, US
Acalabrutinib, ACP-196
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
07/21
09/27
2021-002924-18: A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma Estudio en fase I/II, abierto y multicéntrico para investigar la seguridad, farmacocinética y eficacia de fadraciclib (cyc065), un inhibidor de cdk2/9 oral, en sujetos con tumores sólidos avanzados y linfoma

Not yet recruiting
1/2
354
Europe
Fadraciclib, CYC065, Capsule, hard
Cyclacel Pharmaceuticals, Cyclacel Limited
Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Hormone receptor +, HER-2 negative, and MBC post-CDK4/6 inhibitor, Triple-negative)Basket cohort: tumor types that are suspected to have a related mechanism of action and are not included in previous groups Cáncer de endometrio, cáncer de ovario, cáncer de las vías biliares, carcinoma hepatocelular (CHC), linfoma de linfocitos B, linfoma de linfocitos T, cáncer colorrectal metastásico, cáncer de mama (HER-2 metastásico refractario, receptor hormonal +, HER-2 negativo e inhibidor de MBC post-CDK4 / 6, triple negativo)Cohorte de cesta: tipos de tumores que se sospecha que tienen un mecanismo de acción relacionado y no están incluido en los grupos anteriores, Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer, Other solid tumors Cáncer de endometrio/ovario, cáncer de vías biliares, carcinoma hepatocelular, linfoma de linfocitos B, linfoma de linfocitos T, cáncer colorrectal metastásico, cáncer de mama, otros tumores sólidos., Diseases [C] - Cancer [C04]
 
 
2021-003272-13: A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphoma

Ongoing
1/2
45
Europe
19CP02, 19CP02, Dispersion for infusion
CellPoint B.V., CellPoint B.V.
Relapsed/refractory B-cell non-Hodgkin lymphoma, non-Hodgkin lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT04715217: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Recruiting
1/2
24
RoW
CD19-CD22 CAR-T cells, Fluorine dara marina injection, Cyclophosphamide injection
Shanxi Province Cancer Hospital, Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Lymphoma, B-Cell
10/24
10/25
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
NCT03664635: MB-CART20.1 Lymphoma

Active, not recruiting
1/2
19
Europe
MB-CART20.1, CD20-targeting CAR T Cells, Anti-CD20 CAR T cells
Miltenyi Biomedicine GmbH
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
09/24
09/24
2021-003815-25: A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Un estudio sobre la seguridad y eficacia de las células T con CAR anti-CD19 en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas

Ongoing
1/2
45
Europe
BCN-CP01, BCN-CP01, Dispersion for infusion
CellPoint B.V., CellPoint B.V.
relapsed / refractory Chronic Lymphocytic Leukemia relapsed / refractory Small Lymphocytic Lymphoma leucemia linfocítica crónica (LLC) en recaída o refractaria linfoma linfocítico de células pequeñas (LLCP) en recaída o refractaria, Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Leucemia linfocítica crónicaLinfoma linfocítico de células pequeñas, Diseases [C] - Cancer [C04]
 
 
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-000493-29: Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas Relatlimab + nivolumab nei linfomi nella popolazione pediatrica e nei giovani adulti

Ongoing
1/2
99
Europe
Anti-LAG-3, NIVOLUMAB, [BMS-986016], [BMS-936558], Solution for injection/infusion, Concentrate for solution for injection/infusion, Opdivo
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin classico e Linfoma Non-Hodgkin ricorrente o refrattario, Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin e Linfoma Non-Hodgkin, Diseases [C] - Cancer [C04]
 
 
NCT04440436: Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Recruiting
1/2
52
RoW
IM19 CAR-T Cells, Fludarabine, Cyclophosphamide
Beijing Immunochina Medical Science & Technology Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd.
NHL
06/22
06/35
2022-000222-24: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA Estudio en fase I/II, abierto y multicéntrico para investigar la seguridad, farmacocinética y eficacia de CYC140, un inhibidor de PLK1 oral, en sujetos con tumores sólidos y linfomas avanzados

Not yet recruiting
1/2
330
Europe
CYC140, Capsule, hard
Cyclacel Pharmaceuticals, Cyclacel Limited
ADVANCED SOLID TUMORS AND LYMPHOMA Tumores sólidos y linfomas avanzados, ADVANCED SOLID TUMORS AND LYMPHOMA Tumores sólidos y linfomas avanzados, Diseases [C] - Cancer [C04]
 
 
2018-004336-30: Study of YTB323 in adult patients with CLL/SLL, 3 L + DLBCL, ALL and 1L HR LBCL.

Not yet recruiting
1/2
224
Europe
Rapcabtagene autoleucel, YTB323, Dispersion for infusion, Capsule, hard, Film-coated tablet, IMBRUVICA
Novartis Pharma AG, Novartis Pharma AG
ALL, CLL/SLL and DLBCL, and High-Risk LBCL., Acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and High-Risk large B-cell lymphoma (HR LBCL)., Diseases [C] - Cancer [C04]
 
 
2021-003993-30: Study of IDP-121 in patients with relapsed/refractory hematologic malignancies Estudio de IDP-121 en pacientes con neoplasias hematológicas en recaída/refractarias

Not yet recruiting
1/2
62
Europe
IDP121, Concentrate and solvent for solution for infusion
IDP Discovery Pharma S.L., IDP Discovery Pharma S.L.
Chronic lymphocytic leukemia (CLL)Diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS)High-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH)High-grade B cell lymphoma not otherwise specified (HGBL-NOS)Multiple myeloma (MM) Leucemia linfocítica crónica (CLL)Linfoma difuso de células B grandes sin otra especificación (DLBCL-NOS)Linfoma de células B de alto grado con reordenamiento de doble o triple hit (HGBL-DH/TH)Linfoma de células B de alto grado sin otra especificación (HGBL-NOS)Mieloma múltiple (MM), Chronic lymphocytic leukemia, some types of lymphoma and multiple mieloma. Leucemia linfocítica crónica, algunos tipos de linfoma y mieloma múltiple., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Recruiting
1/2
72
RoW
EBViNT Cell, Eutil autologous blood-derived T lymphocytes
Eutilex
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
09/22
12/24
NCT03586999: Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Active, not recruiting
1/2
18
US
Nivolumab, Opdivo, Etoposide, Vepesid, Toposar, Prednisolone, Oraped, PediaPred, Millipred, Oncovin, Vincristine, Leurocristine, Cyclophosphamide, cytophosphane, Hydroxydaunorubicin, Adriamycin
University of Colorado, Denver, Bristol-Myers Squibb
Peripheral T Cell Lymphoma
09/22
12/24
PrE0404, NCT03323151: A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Completed
1/2
43
US
Ixazomib, Ninlaro, Ibrutinib, Imbruvica
PrECOG, LLC., Takeda
Mantle-Cell Lymphoma
09/22
09/23
PARADIGME, NCT01796171 / 2011-000033-36: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Hourglass Jul 2018 - Dec 2018 : Completion of enrollment in pivotal P2 PARADIGME trial
Checkmark LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Nov 2018 - Nov 2018: LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Hourglass Oct 2016 - Dec 2016 : Dose escalation in arm 1 and either arm 3 or 4 of P1/2 Lymrit 37-01 trial for FL
Hourglass Oct 2016 - Dec 2016 : SRC review of data from arms 3 and 4 of P1/2 Lymrit 37-01 trial for FL
More
Completed
1/2
191
Europe, Canada, US, RoW
10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin
Nordic Nanovector, ICON Clinical Research
Non-Hodgkin Lymphoma, Follicular Lymphoma
10/22
10/22
2022-001136-28: A dose-finding and dose expansion study of OSE-279 in subjects with advanced solid tumors or lymphomas

Not yet recruiting
1/2
24
Europe
OSE-279, OSE-279, Concentrate for solution for infusion
OSE Immunotherapeutics, OSE Immunotherapeutics
Advanced solid tumors and lymphomas, Solid tumors and lymphomas, Diseases [C] - Cancer [C04]
 
 
NCT03422679 / 2017-001491-35: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Terminated
1/2
79
Europe, US, RoW
CB-103
Cellestia Biotech AG
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
11/22
11/22
2018-001923-38: A Phase 1/2 Multicenter Study of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Not yet recruiting
1/2
108
Europe, RoW
KTE-X19, KTE-X19, Dispersion for infusion
Kite Pharma, Inc, KITE PHARMA INC., Kite Pharma, Inc
Relapsed/Refractory Chronic Lymphocytic Leukemia, Cancers of white blood cells, Diseases [C] - Cancer [C04]
 
 
NCT04358458 / 2019-002752-16: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Terminated
1/2
46
Europe, US
GEN3009, DuoHexaBody®-CD37, Epcoritamab, DuoBody®-CD3xCD20, GEN3013, EPKINLY™
Genmab, AbbVie
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
11/22
07/23
2021-006234-39: A study of GB5121 in adults with cancer of the central nervous system that has reappeared or did not respond to prior therapy Un estudio de GB5121 en adultos con cáncer del sistema nervioso central que ha reaparecido o no ha respondido a la terapia anterior

Ongoing
1/2
143
Europe
GB5121, Capsule, soft
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB005, Inc.
Relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphoma Linfoma primario o secundario del sistema nervioso central o linfoma vitreorretiniano primario recidivante/resistente al tratamiento, Cancer of the central nervous system Cáncer del sistema nervioso central, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03932331: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Calendar Jan 2024 - Dec 2025: Final data readout from trial for CLL
Hourglass Jan 2023 - Mar 2023 : Second data readout from cohort B of P1/2 trial for CLL
Hourglass Jul 2022 - Dec 2022 : Data from P2 portion of P1/2 trial for MCL
Hourglass Jul 2022 - Sep 2022 : Final data readout from trial for MCL
Hourglass Jul 2022 - Sep 2022 : First data readout from cohort B of P1/2 trial for CLL
Active, not recruiting
1/2
105
RoW
Acalabrutinib
AstraZeneca
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
12/22
12/23
NCT05189093: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Recruiting
1/2
99
RoW
Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
Waterstone Hanxbio Pty Ltd
Relapsed/Refractory Lymphoma
12/22
08/23
NCT03493217: A Study to Evaluate ICP-022 in Patients With CLL/ SLL

Active, not recruiting
1/2
100
RoW
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
CLL/SLL
12/22
12/22
NCT05155215: Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Not yet recruiting
1/2
68
NA
IM19 CAR-T cells, Cyclophosphamide, Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Lymphoma, Lymphoma, Mantle-Cell, Neoplasms by Histologic Type, Neoplasms, Lymphoproliferative Disorders
12/22
02/23
Epi-RCHOP, NCT02889523 / 2016-001499-31: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Calendar Jan 2023 - Dec 2024: Data from P1b/2 trial for DLBCL and follicular lymphoma
Checkmark Initial combination data
Dec 2018 - Dec 2018: Initial combination data
Not Appicable May 2018 - May 2018 : Epi-RCHOP trial in 1L DLBCL [Trial suspended]
Checkmark Transition into P2 in P1/2 Epi-RCHOP trial in frontline DLBCL
More
Active, not recruiting
1/2
214
Europe
Tazemetostat, EPZ-6438, Rituximab, Mabthera, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone
The Lymphoma Academic Research Organisation, Epizyme, Inc.
Lymphoma, DLBCL, Follicular Lymphoma
01/23
04/26
NCT03458728 / 2017-000383-15: Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Terminated
1/2
31
US
Copanlisib (BAY806946)
Bayer, Bayer AG
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
02/23
02/23
2022-000891-20: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies Estudio abierto, con escalado de dosis y expansión de dosis, para evaluar la seguridad, la farmacocinética, la farmacodinámica y la actividad clínica del CA‑4948 administrado por vía oral en pacientes con neoplasias hematológicas en recaída o refractarias

Not yet recruiting
1/2
221
Europe
Ibrutinib, CA-4948, Film-coated tablet, Imbruvica
Curis, Inc., Curis, Inc.
Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Relapsed or Refractory Hematologic Malignancy Neoplasias hematológicas en recaída o refractarias, Diseases [C] - Cancer [C04]
 
 
NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Terminated
1/2
25
RoW
ADG106 injection, PD-1 antibody injection
Adagene (Suzhou) Limited
Solid Tumor, Non Hodgkin Lymphoma
02/23
02/23
NCT05028478: A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Not yet recruiting
1/2
164
NA
CN202
Curon Biopharmaceutical (Australia) Co Pty Ltd, Novotech (Australia) Pty Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Hematologic Malignancies
02/23
10/23
PLATFORM, NCT03310619: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Checkmark PLATFORM trial in combination with JCAR017
Sep 2018 - Sep 2018: PLATFORM trial in combination with JCAR017
Completed
1/2
62
US
JCAR017, Durvalumab, MEDI4736, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Celgene
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
02/23
02/23
KEYNOTE-A10, NCT03058289: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Checkmark Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Nov 2021 - Nov 2021: Data from IT-01 trial in combination with INT230-6 in metastatic sarcomas at CTOS 2021
Completed
1/2
110
Canada, US
INT230-6, anti-PD-1 antibody, pembrolizumab, Keytruda, MK-3475, anti-CTLA-4 antibody, ipilimumab, Yervoy, BMS-734016
Intensity Therapeutics, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
02/23
02/23
NCT04323657: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Completed
1/2
6
US
TC-110 T Cells, Fludarabine, Cyclophosphamide
TCR2 Therapeutics
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
02/23
02/23
NCT03837899 / 2018-003118-42: Durvalumab and Tremelimumab for Pediatric Malignancies

Active, not recruiting
1/2
56
Europe, US
Durvalumab / Tremelimumab Combination Therapy, durvalumab: Imfinzi, MEDI4736, tremelimumab: CP-675,206
AstraZeneca
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
02/23
12/24
NCT04602065: Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Terminated
1/2
9
RoW
IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
Innovent Biologics (Suzhou) Co. Ltd.
Extranodal NK/T Cell Lymphoma, Nasal Type
02/23
02/23
NCT04762485: Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia

Recruiting
1/2
20
RoW
Humanized CD7 CAR-T cells
The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
02/23
02/24
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated
1/2
23
RoW
TQ-B3525 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
11/23
11/23
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Recruiting
1/2
73
RoW
CAR-T cell immunotherapy
Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University
B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma
03/23
03/23
2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología.

Not yet recruiting
1/2
27
Europe
TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml
Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III
Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04]
 
 
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
2020-002464-31: A study to evaluate the safety and efficacy of KRT-232 in combination with Acalabrutinib in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia. Vizsgálat az acalabrutinibbel együtt adott KRT-232 biztonságosságának és hatásosságának értékelésére relapszált/refrakter diffúz nagy B-sejtes limfómában vagy relapszált/refrakter krónikus limfocitás leukémiában szenvedő betegeknél

Not yet recruiting
1/2
114
Europe, RoW
Acalabrutinib, KRT-232, Tablet, Capsule, hard, CALQUENCE
Kartos Therapeutics Inc., Kartos Therapeutics, Inc, Kartos Therapeutics, Inc.
- Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL)- R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhibitor- R/R DLBCL with non-germinal center B-cell like(GCB) subtype- R/R DLBCL with double-expressor lymphoma subtype, - Relapsed/Refractory Diffuse Large B-cell Lymphoma- Relapsed/Refractory Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
TAK-981-1501, NCT04074330: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Terminated
1/2
38
Europe, Canada, Japan, US, RoW
TAK-981, Rituximab
Takeda
Lymphoma, Non-Hodgkin
04/23
04/23
2020-003946-36: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Lymphoma

Not yet recruiting
1/2
180
Europe
NA, Rituximab, TAK-981, Concentrate for solution for infusion, MabThera
Takeda Development Center Americas, Inc., TAKEDA DEVELOPMENT CENTER AMERICAS INC., Takeda Development Center Americas, Inc. (TDC Americas)
Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma, Lymphoma, Diseases [C] - Cancer [C04]
 
 
PROCLAIM-CX-2029, NCT03543813 / 2018-001456-34: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Completed
1/2
133
Europe, US, RoW
CX-2029
CytomX Therapeutics
Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
06/23
06/23
NCT05269940: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Recruiting
1/2
70
RoW
ZX-101A
Nanjing Zenshine Pharmaceuticals
Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL
04/23
07/24
NCT05351593: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Recruiting
1/2
35
US
Tafasitamab, MOR208, Lenalidomide, Revlimid
James Rubenstein, Incyte Corporation
CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
09/25
06/26
NCT04836507: Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

Recruiting
1/2
91
RoW
CRC01, Fludarabine, Cyclophosphamide
Curocell Inc.
Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)
05/23
02/28
NCT05400876: To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Recruiting
1/2
92
RoW
TQB2618 injection, Penpulimab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Lymphoma
05/23
10/23
NCT02282358: Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Hourglass Jan 2017 - Dec 2018 : Single arm registration trial in 2nd-line DLBCL in 2017/2018
Terminated
1/2
7
US
Mocetinostat
Memorial Sloan Kettering Cancer Center, MethylGene Inc.
Lymphoma, Relapsed and Refractory, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
05/23
05/23
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996, Nanatinostat, Valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT03187210: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Suspended
1/2
20
Europe
Brentuximab Vedotin, BeEAM Regimen
Insel Gruppe AG, University Hospital Bern, Mundipharma Medical Company
Lymphoma
11/23
11/24
2022-003618-35: A study to determine the best dose, the efficacy, and safety of mocravimod in patients with large B cell lymphoma treated with genetically modified immune cells (CD19 CAR T cells)

Not yet recruiting
1/2
30
Europe
mocravimod, KRP203, Capsule, hard
Priothera S.A.S., Priothera S.A.S.
Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Patients with large B cell lymphoma treated with a CD19 CAR T therapy, Diseases [C] - Cancer [C04]
 
 
2022-002989-33: CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY:THE COLPRIT PHASE I/II STUDY

Not yet recruiting
1/2
38
Europe
90Y-Pentixather, Solution for injection in vial
Klinikum rechts der Isar der Technischen Universität München, Klinikum rechts der Isar der Technischen Universität München
Indication: Non-Hodgkin lymphomas (NHL)Advanced lymphoproliferative cancers: aggressive B- and T- cell Non-Hodgkin lymphomas (NHL), including heavily pretreated transformed indolent lymphoma (tNHL) and multiple myeloma (MM) as a subgroup of B-cell NHL, Non-Hodgkin lymphomas (NHL), Diseases [C] - Cancer [C04]
 
 
NCT03590574 / 2017-001965-26: Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Recruiting
1/2
200
Europe
AUTO4
Autolus Limited
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
07/23
07/25
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
2021-003410-39: Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 in Patients with Advanced Non-Hodgkin Lymphoma Evaluar la Seguridad, Tolerabilidad, Farmacoquinética y Eficacia Preliminar de AZD0466 en Pacientes con Linfoma no Hodgkin Avanzado

Not yet recruiting
1/2
49
Europe
AZD0466 powder for concentrate for solution for infusion, AZD0466, Powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Advanced Non-Hodgkin Lymphoma Linfoma no Hodgkin avanzado, Lymphoma Linfoma, Diseases [C] - Cancer [C04]
 
 
CHAMP-1, NCT05487170: A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma

Recruiting
1/2
105
US
RNK05047
Ranok Therapeutics (Hangzhou) Co., Ltd.
Advanced Solid Tumor, DLBCL
02/24
10/24
GO40554, NCT03677154 / 2018-001127-40: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Checkmark First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Feb 2021 - Feb 2021: First-patient-in for cohort C of P1 trial for 1L elderly/unfit DLBCL
Checkmark Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for elderly/unfit 1L DLBCL at ASH 2020
Active, not recruiting
1/2
188
Europe, US, RoW
Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
08/25
08/25
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
08/24
03/25
NCT01484093: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Completed
1/2
96
US
R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR., HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE (ASCR)Patients admitted to the hospital for high dose chemotherapy. The anticipated length of, stay is 3-4 weeks. 14 days ± 1 day following the administration of the therapeutic dose of Iodine 131 I, Tositumomab, patients will be admitted for high-dose chemotherapy. BEAM, will be administered
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
08/23
08/23
NCT02632396: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Active, not recruiting
1/2
12
US
Ixazomib, Ninlaro, MLN9708, Ixazomib Citrate, Rituximab, Rituxan, MabThera, Chimeric Anti-CD20 Antibody
Emory University, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Mantle Cell Lymphoma
08/23
08/24
NCT05205161: A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Terminated
1/2
7
Europe, US, RoW
AZD0466
AstraZeneca
Non-Hodgkin Lymphoma
08/23
08/23
ACE-LY-003, NCT02180711: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Calendar Jan 2024 - Dec 2024: From trial for r/r follicular lymphoma
Hourglass Jul 2023 - Sep 2023 : Last patient dosing of P1 ACE-LY-003 trial for relapsed/refractory follicular lymphoma
Active, not recruiting
1/2
113
Europe, Canada, US
acalabrutinib, ACP-196, rituximab (IV), Lenalidomide
Acerta Pharma BV, AstraZeneca
Non Hodgkin Lymphoma
08/23
12/28
NCT03246750: B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

Completed
1/2
34
RoW
B-MAD chemotherapy, Involved field radation, cisplatin
The Thai Lymphoma Study Group, Takeda
Extranodal NK/T-cell Lymphoma
04/24
04/24
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23
HLX301, NCT05390528: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of (TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

Recruiting
1/2
30
RoW
HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody
Shanghai Henlius Biotech
Advanced Tumors, Lymphoma, Metastatic Tumors
09/23
12/24
2020-004583-26: A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia

Not yet recruiting
1/2
222
Europe
LAVA-051, LAVA-051, Concentrate for solution for injection/infusion
LAVA Therapeutics N.V., LAVA Therapeutics NV, LAVA Therapeutics B.V., LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML), Patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01755975: Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
62
US
Romidepsin, Lenalidomide
Memorial Sloan Kettering Cancer Center, Saint Francis/Mount Sinai Regional Cancer Center, Weill Medical College of Cornell University, University of Nebraska, Celgene Corporation, Biologics, Inc.
Multiple Myeloma, Non-Hodgkin's Lymphoma
10/23
10/23
IGM-2323-001, NCT04082936 / 2021-002339-44: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Hourglass Jan 2022 - Dec 2022 : Initial data from trial for DLBCL/follicular lymphoma
Hourglass Jan 2021 - Dec 2021 : Completion of enrollment of P1 trial for NHL
Checkmark Safety and efficacy data from trial for r/r NHL at ASH 2021
Dec 2021 - Dec 2021: Safety and efficacy data from trial for r/r NHL at ASH 2021
Checkmark Interim data from trial for r/r NHL at ASH 2020
More
Active, not recruiting
1/2
97
Europe, US, RoW
imvotamab
IGM Biosciences, Inc., ADC Therapeutics S.A.
Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
10/24
10/24
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting
1/2
118
Europe
Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq®
F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd
Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04]
 
 
NCT03576378 / 2017-003689-28: BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
41
Europe
BrentuximabVedotin (BV), cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Takeda
Hodgkin Lymphoma
10/23
10/24
CYC065-101, NCT04983810: A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Recruiting
1/2
330
Europe, US, RoW
Fadraciclib, CYC065
Cyclacel Pharmaceuticals, Inc.
Solid Tumor, Adult, Lymphoma
04/25
06/25
topMIND, NCT04809467 / 2020-005591-35: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Hourglass Jan 2023 - Dec 2023 : Proof-of-concept data from TopMIND trial in combination with parsaclisib for r/r NHL or CLL
Active, not recruiting
1/2
54
Europe, US
tafasitamab, INCMOR00208, parsaclisib, INCB050465
Incyte Corporation
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
12/24
12/24
 

Download Options